Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: A 24-week, randomized, open-label, follow-up study in China

Zou, Li‐Ping; Wang, Xu; Dong, Changhong; Chen, Chunhong; Zhao, Wei; Zhao, Ruo-Yan

doi:10.1016/j.clinthera.2010.04.008

Cited by 45 publications

(54 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Magnesium and MgVPA have been successfully employed in other epileptic and learning disorders (Dósa et al 2010;Zou et al 2010;Porras-Kattz et al 2011). For example, Mg has been used to mitigate refractory status epilepticus in patients with POLG-1 mutations (Pandey et al 2010;Visser et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Efficacy of Magnesium Valproate in Succinic Semialdehyde Dehydrogenase Deficiency

et al. 2012

View full text Add to dashboard Cite

Succinic semialdehyde dehydrogenase deficiency (SSADHD), a disorder of g-aminobutyric acid (GABA) metabolism, manifests typically as a nonprogressive neurodevelopmental disorder with cognitive deficiency, neuropsychiatric morbidity and epilepsy. Therapy targets symptomatic seizures and neurobehavioral disturbances. We report an adolescent female with SSADHD whose unresponsiveness to a broad spectrum of antiepileptics was circumvented with magnesium valproate (MgVPA). Epilepsy remains well controlled in our patient, with concomitant improvements in behavioral symptoms and an absence of adverse symptoms. MgVPA intervention may have utility in SSADHD.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Efficacy of Magnesium Valproate in Succinic Semialdehyde Dehydrogenase Deficiency

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[38][39][40][41][42][43][44][45][46][47][48][49][50][51] A total of 1218 infants (age range = 0-24 months) were randomized to ACTH, prednisolone, prednisone, GVG, NZP, TPM, LEV, or PLB and followed for 1 week to 6.4 months ( Table 1). [38][39][40][41][42][43][44][45][46][47][48][49][50][51] A total of 1218 infants (age range = 0-24 months) were randomized to ACTH, prednisolone, prednisone, GVG, NZP, TPM, LEV, or PLB and followed for 1 week to 6.4 months ( Table 1).…”

Section: Infantile Spasms-west Syndromementioning

confidence: 99%

Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta‐analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In a small, open-label study (Level 2b) on infantile spasms, adding MgSO 4 to ACTH resulted in improvement in the resolution of seizures (183). A small, retrospective, chart review (Level 4) suggested that adjunctive oral Mg treatment resulted in substantial improvement in seizure frequency in patients with refractory epilepsy (184).…”

Section: Novel Treatmentsmentioning

confidence: 99%

A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel

Frye

Rossignol²,

Casanova

et al. 2013

Front. Public Health

View full text Add to dashboard Cite

Despite the fact that seizures are commonly associated with autism spectrum disorder (ASD), the effectiveness of treatments for seizures has not been well studied in individuals with ASD. This manuscript reviews both traditional and novel treatments for seizures associated with ASD. Studies were selected by systematically searching major electronic databases and by a panel of experts that treat ASD individuals. Only a few anti-epileptic drugs (AEDs) have undergone carefully controlled trials in ASD, but these trials examined outcomes other than seizures. Several lines of evidence point to valproate, lamotrigine, and levetiracetam as the most effective and tolerable AEDs for individuals with ASD. Limited evidence supports the use of traditional non-AED treatments, such as the ketogenic and modified Atkins diet, multiple subpial transections, immunomodulation, and neurofeedback treatments. Although specific treatments may be more appropriate for specific genetic and metabolic syndromes associated with ASD and seizures, there are few studies which have documented the effectiveness of treatments for seizures for specific syndromes. Limited evidence supports l-carnitine, multivitamins, and N-acetyl-l-cysteine in mitochondrial disease and dysfunction, folinic acid in cerebral folate abnormalities and early treatment with vigabatrin in tuberous sclerosis complex. Finally, there is limited evidence for a number of novel treatments, particularly magnesium with pyridoxine, omega-3 fatty acids, the gluten-free casein-free diet, and low-frequency repetitive transcranial magnetic simulation. Zinc and l-carnosine are potential novel treatments supported by basic research but not clinical studies. This review demonstrates the wide variety of treatments used to treat seizures in individuals with ASD as well as the striking lack of clinical trials performed to support the use of these treatments. Additional studies concerning these treatments for controlling seizures in individuals with ASD are warranted.

show abstract

Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: A 24-week, randomized, open-label, follow-up study in China

Cited by 45 publications

References 23 publications

Therapeutic Efficacy of Magnesium Valproate in Succinic Semialdehyde Dehydrogenase Deficiency

Therapeutic Efficacy of Magnesium Valproate in Succinic Semialdehyde Dehydrogenase Deficiency

Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta‐analysis

A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel

Contact Info

Product

Resources

About